Termine
Performance
03.12.2021

25.05.21 Instone Real Estate Group SE
Roadshow
25.05.21 centrotherm international AG
Veröffentlichung Konzern-/Jahresabschluss
25.05.21 TeamViewer AG
Roadshow
25.05.21 MBB SE
Veröffentlichung Quartalsmitteilung (Stichtag Q1)
25.05.21 DATAGROUP SE
Veröffentlichung Halbjahresabschluss
25.05.21 Petro Welt Technologies AG
Veröffentlichung Quartalsfinanzbericht (Stichtag Q1)

Dezember

KW M D M D F S S
48     1 2 3 4 5
49 6 7 8 9 10 11 12
50 13 14 15 16 17 18 19
51 20 21 22 23 24 25 26
52 27 28 29 30 31    

Januar 2022

KW M D M D F S S
52           1 2
1 3 4 5 6 7 8 9
2 10 11 12 13 14 15 16
3 17 18 19 20 21 22 23
4 24 25 26 27 28 29 30
5 31            

Februar 2022

KW M D M D F S S
5   1 2 3 4 5 6
6 7 8 9 10 11 12 13
7 14 15 16 17 18 19 20
8 21 22 23 24 25 26 27
9 28            

 

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021